Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 11/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645363 | 0.87 | KMO (0.65) | KMOEGFRERBB3P4HTM | |
| SCHEMBL14770745 | 0.83 | KMO (0.60) | KMOEGFRERBB3KCNQ3KCNQ2 | |
| SCHEMBL13472424 | 0.82 | ABL1 (0.57) | KMOEGFRERBB3 | |
| SCHEMBL13472418 | 0.80 | KMO (0.56) | KMOEGFRERBB3IDO1TDO2 | |
| SCHEMBL13474095 | 0.80 | KMO (0.56) | KMOEGFRERBB3KCNQ3KCNQ2 | |
| SCHEMBL3221134 | 0.79 | KMO (0.67) | KMOEGFRERBB3S1PR1 | |
| SCHEMBL3226900 | 0.79 | KMO (0.66) | KMOEGFRERBB3S1PR1 | |
| SCHEMBL13472421 | 0.78 | KMO (0.51) | KMOIDO1TDO2 | |
| SCHEMBL13472427 | 0.76 | KMO (0.62) | KMOEGFRERBB3S1PR1 | |
| SCHEMBL13472428 | 0.74 | KMO (0.50) | KMOEGFRERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885EGFR 558/4885ERBB3 161/4885 |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KMO 3678/4885EGFR 558/4885ERBB3 161/4885 |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885EGFR 558/4885ERBB3 161/4885 |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885EGFR 558/4885ERBB3 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.